Brief: Hyloris Announces Launch Of Maxigesic® Iv In U.S. And Approval In Canada
27/02/2024 17:01
Hyloris Pharmaceuticals SA HYL.BR :
* HYLORIS ANNOUNCES LAUNCH OF MAXIGESIC® IV IN U.S. AND
APPROVAL
IN CANADA
Source text for Eikon: ID:nGNEbqHg1X
Further company coverage: HYL.BR
Recent news on Hyloris Pharmaceuticals SA
See all newsEurope Research Roundup: Akzo Nobel, MTU Aero Engines, Symrise
Brief: Hyloris Pharmaceuticals Says It Obtains Exclusive License Rights In Europe & Turkey From Arbormed For Its Wilson's Disease Therapy
Brief: Hyloris Announces Partnership With Rosemont Pharmaceuticals For Atomoxetine Oral Solution In The U.S.
Brief: Hyloris Announces Positive Study Results For Dofetilide IV
Brief: Hyloris Pharmaceuticals SA Says HY 2024 Revenues (Royalties And Milestones) Increased To EUR 4,2 Million